New drug duo aims to shrink breast tumors before surgery
NCT ID NCT05069038
First seen Dec 29, 2025 · Last updated May 10, 2026 · Updated 16 times
Summary
This study tests whether giving a targeted drug (palbociclib) along with hormone therapy before surgery can shrink tumors in people with early-stage hormone receptor-positive, HER2-negative breast cancer. About 51 participants will receive the combination for several weeks before their operation. The goal is to improve surgical outcomes and understand how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unversity of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.